153 related articles for article (PubMed ID: 9260987)
1. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men.
Price DA; De'Oliveira JM; Fisher ND; Hollenberg NK
Hypertension; 1997 Aug; 30(2 Pt 1):240-6. PubMed ID: 9260987
[TBL] [Abstract][Full Text] [Related]
2. Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans.
Osei SY; Price DA; Laffel LM; Lansang MC; Hollenberg NK
Hypertension; 2000 Jul; 36(1):122-6. PubMed ID: 10904023
[TBL] [Abstract][Full Text] [Related]
3. A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men.
Ilson BE; Boike SC; Martin DE; Freed MI; Zariffa N; Jorkasky DK
Clin Pharmacol Ther; 1998 Apr; 63(4):471-81. PubMed ID: 9585802
[TBL] [Abstract][Full Text] [Related]
4. Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.
Brodsky S; Gurbanov K; Abassi Z; Hoffman A; Ruffolo RR; Feuerstein GZ; Winaver J
Hypertension; 1998 Oct; 32(4):746-52. PubMed ID: 9774374
[TBL] [Abstract][Full Text] [Related]
5. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
Fisher ND; Jan Danser AH; Nussberger J; Dole WP; Hollenberg NK
Circulation; 2008 Jun; 117(25):3199-205. PubMed ID: 18559696
[TBL] [Abstract][Full Text] [Related]
6. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
[TBL] [Abstract][Full Text] [Related]
7. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition.
De'Oliveira JM; Price DA; Fisher ND; Allan DR; McKnight JA; Williams GH; Hollenberg NK
Kidney Int; 1997 Sep; 52(3):771-7. PubMed ID: 9291199
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.
Ohlstein EH; Brooks DP; Feuerstein GZ; Ruffolo RR
Pharmacology; 1997 Nov; 55(5):244-51. PubMed ID: 9399334
[TBL] [Abstract][Full Text] [Related]
9. Acute eprosartan-induced intrarenal vasodilation in hypertensive humans is not influenced by dietary sodium intake or angiotensin II co-infusion.
van Twist DJ; Houben AJ; de Leeuw PW; Kroon AA
J Hypertens; 2016 Aug; 34(8):1607-14. PubMed ID: 27214088
[TBL] [Abstract][Full Text] [Related]
10. Clinical profile of eprosartan.
Puig JG; López MA; Bueso TS; Bernardino JI; Jiménez RT;
Cardiovasc Drugs Ther; 2002 Dec; 16(6):543-9. PubMed ID: 12766389
[TBL] [Abstract][Full Text] [Related]
11. Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans.
Vase H; Lauridsen TG; Bech JN; Pedersen EB
Br J Clin Pharmacol; 2008 Jun; 65(6):822-32. PubMed ID: 18341678
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
Brooks DP; Ruffolo RR
J Hypertens Suppl; 1999 Jun; 17(2):S27-32. PubMed ID: 10465064
[TBL] [Abstract][Full Text] [Related]
13. The renal profile of eprosartan.
Sica DA; Hollenberg NK
Pharmacotherapy; 1999 Apr; 19(4 Pt 2):86S-94S. PubMed ID: 10213527
[TBL] [Abstract][Full Text] [Related]
14. Central inhibition of AT1receptors by eprosartan--in vitro autoradiography in the brain.
Muders F; Palkovits M; Bahner U; Kirst I; Elsner D; Jandeleit-Dahm K
Pharmacol Res; 2001 Mar; 43(3):251-5. PubMed ID: 11401417
[TBL] [Abstract][Full Text] [Related]
15. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data.
Brooks DP; Ohlstein EH; Ruffolo RR
Am Heart J; 1999 Sep; 138(3 Pt 2):246-51. PubMed ID: 10467220
[TBL] [Abstract][Full Text] [Related]
17. Renal hemodynamic and hormonal responses to the angiotensin II antagonist candesartan.
Lansang MC; Osei SY; Price DA; Fisher ND; Hollenberg NK
Hypertension; 2000 Nov; 36(5):834-8. PubMed ID: 11082152
[TBL] [Abstract][Full Text] [Related]
18. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
Gavras I; Gavras H
Curr Med Res Opin; 1999; 15(1):15-24. PubMed ID: 10216807
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin blockade with eprosartan: vascular and functional implications.
Ram CV
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
[TBL] [Abstract][Full Text] [Related]
20. AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain.
Heusser K; Vitkovsky J; Schmieder RE; Schobel HP
Auton Neurosci; 2003 Aug; 107(1):45-51. PubMed ID: 12927226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]